| Popis: |
Background & aim: Lymphocytic leukemia (CLL) is the most common type of leukemia in young people in Western countries with a diverse clinical course. Cur cumin is a biologically active ingredient in turmeric, which has extensive biological properties, such as; anti-inflammatory, antioxidant, anti-diabetic and anti-cancer. The aim of the present study was to determine the effects of curcumin on inhibiting growth and reducing gene expression in lymphocytic leukemia (CLL-CII) cells. Methods: In the present experimental study conducted in 2019, CLL-CII cancer cells in three groups: control group, placebo, and a group treated with different concentrations of curcumin, including; 2.5, 5, 7.5 and 10μM were incubated for 24, 48 and 72 hours to assess bioavailability and PML gene expression. Subsequently, biological ability was analyzed using MTT ELISA Rider device and PML gene expression through RT-Real Time-PCR data analysis. Data analysis was performed using SPSS software, version 18 and one-way analysis of variance (ANOVA) and Duncan test. Results: The results of the present study suggested that cur cumin at concentration of 2.5 μm of significantly reduced the bioavailability of CLL-CII cells compared to other experimental groups at all three incubation times. Correspondingly, treatment with cur cumin significantly reduced the expression of PML gene expression in other experimental groups compared to the control and placebo groups (P=0.032). Conclusion: Considering the inhibitory effect of cur cumin on the growth, proliferation and invasion of lymphocytic leukemia cells and also on the potential function of PML-RARα angiogenesis in these cells by reducing the expression of PML gene, it seemed that the active component of turmeric (cur cumin) in Prevention and treatment of lymphocytic leukemia had satisfactory consequences. |
